Compare Quest Diagnostics Inc (DGX) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kraft Heinz Co — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Kraft Heinz Co trades at $25.51 (market cap $29.74B). The key difference: Kraft Heinz Co is the larger of the two by market cap, and Kraft Heinz Co pays the higher dividend (6.38%). Which is the better fit depends on your goals.
| DGX | KHC | |
|---|---|---|
Market Cap | $22.80B | $29.74B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $28.94 |
52-Week Low | $166.42 | $21.21 |
Enterprise Value | $28.82B | $46.78B |
Dividend Yield | 1.67% | 6.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Kraft Heinz (KHC) trades at $25.23, up 1.53% with a bullish technical trend and strong recent earnings beats. The stock shows attractive valuation metrics with a P/E of 13.04 and P/B of 0.71, though profitability remains challenged with negative net income margins. Recent corporate restructuring aims to accelerate growth, while a 6.4% dividend yield provides income support. Cash flow trends have improved significantly from 2022's negative $2.4B to 2025's positive $1.46B.
The outlook remains cautious despite technical strength. While undervaluation and dividend yield offer appeal, persistent negative profitability and high debt levels pose significant risks. Analyst consensus is predominantly Hold with a $23.50 price target below current levels, suggesting limited near-term upside potential amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
